PALLAS

What PALLAS does

PALLAS, operating as NRG PALLAS, is a Dutch nuclear technology organisation that produces medical isotopes through reactor irradiations and delivers nuclear energy and radiation protection services to institutional customers in the Netherlands and abroad. The company operates the High Flux Reactor (HFR) at Petten and produces a portfolio of radioisotopes — Molybdenum-99, Lutetium-177, Terbium-161, Yttrium-90, and Iridium-192 — alongside radiochemicals such as Lutetium-177 n.c.a. and Lead-212 that serve diagnostic imaging and targeted radionuclide therapy. These isotopes are reported to help approximately 30,000 cancer patients per day worldwide, with named end users including the Netherlands Cancer Institute (Antoni van Leeuwenhoek) where Lutetium-177 is used for prostate cancer treatment.

The organisation's core technology stack rests on nuclear reactor operations, hot-cell infrastructure, radiochemical processing, and irradiation services. The flagship strategic initiative is the PALLAS New-build programme — a replacement reactor in Petten intended to secure long-term global supply of medical isotopes — supported by critical supply-chain partnerships such as the FCC (Grupo FCC) agreement for hot-cell installation. Complementing isotope production, NRG PALLAS provides nuclear facility services including in-service inspections, licensing, safety analyses, long-term operation management, fuel management, waste management and decommissioning, plus dedicated radiation protection services (operational support, laboratory services, measuring/monitoring/calibrations, and the ReGuard monitoring system). The NRG PALLAS Academy delivers certified radiation protection training (RPE, RPO courses), and research activities span medical research programmes (ILLUMINATE, SECURE) and nuclear energy research into safe climate-neutral energy.

The business model is B2B and B2G (government), with quote-based pricing that is not publicly disclosed. Distribution is direct to enterprise and institutional customers: hospitals and cancer treatment centres for isotopes, nuclear facility operators for engineering and compliance services, and nuclear industry professionals for Academy training. The firm is private (no public listing disclosed), reports 11–50 employees in the limited firmographic data, and operates from Alkmaar, Petten, and Arnhem in the Netherlands, with global reach via isotope supply. Revenue is not publicly disclosed and ownership structure is not characterised in the provided sources.

Name

PALLAS

Legal name

NRG PALLAS

Website

https://pallasreactor.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

PALLAS (operating as NRG PALLAS) is a Dutch nuclear technology organisation that produces medical isotopes via reactor irradiations and provides nuclear energy, radiation protection, and training services to healthcare providers, nuclear facility operators, and research institutions worldwide.

Ownership category

akta.pro rank

Product category

Medical Isotope Production and Nuclear Energy Services

NAICS

Irradiation Apparatus Manufacturing (334517), Hazardous Waste Treatment and Disposal (562211), Remediation Services (562910), Medical and Diagnostic Laboratories (6215)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844), Hazardous Waste Management (4955), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA)

akta.pro secondary industries

Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain) (EUAKAIAE), Transport & Storage Cask Testing, Certification & Maintenance (EUAKAHAE)

Keywords

• Medical isotope production
• Nuclear energy services
• Radiation protection services
• Radiopharmaceutical manufacturing
• Nuclear reactor operations

Headquarters

HQ city

Alkmaar

HQ country

Netherlands

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Distribution channels3 records

Marketing channels5 records

Core offering

NRG PALLAS operates the High Flux Reactor (HFR) in Petten, Netherlands to produce medical isotopes including Molybdenum-99, Lutetium-177, Terbium-161, Yttrium-90, and Iridium-192 for cancer diagnosis and treatment, serving approximately 30,000 patients daily. The organization is also constructing the new PALLAS reactor to replace the HFR and secure long-term global medical isotope supply. Additionally, it provides nuclear energy services including reactor safety analyses, licensing support, in-service inspections, waste management, and radiation protection for existing and new nuclear facilities, alongside training through the NRG PALLAS Academy.

Product overview

NRG PALLAS is a nuclear technology organization offering a portfolio of interconnected products and services centered on nuclear medicine and nuclear energy. The core offerings include Medical Isotope Solutions (radioisotopes like Lutetium-177, Molybdenum-99, and radiochemicals) for diagnosing and treating diseases, Nuclear Energy Services (supporting existing and new reactors through licensing, safety analyses, and waste management), the PALLAS Academy for radiation protection training, and the PALLAS Programme for constructing a new reactor to replace the aging High Flux Reactor. The company supports over 30,000 cancer patients daily with its medical isotope products and is developing nuclear infrastructure to ensure long-term global medical isotope supply.

Differentiator

Problem solved

Functional benefit

Brands

• PALLAS Programme: The dedicated project organization responsible for the construction of the new PALLAS reactor and its supporting infrastructure in Petten
• NRG PALLAS Academy

Products and services

• Medical Isotope Solutions Nuclear irradiation services producing medical isotopes (Molybdenum-99, Lutetium-177, Terbium-161, Yttrium-90, Iridium-192) and radiochemicals (Lutetium-177 n.c.a., Lead-212) for healthcare providers, hospitals, cancer treatment centers, and medical research institutions. Supports diagnostic imaging and therapy for approximately 30,000 patients daily.
• Nuclear Energy Services Comprehensive nuclear technology services for the safe operation of reactors and nuclear facilities, including licensing, safety analyses, in-service inspections, long-term operation management, fuel management, radioactive waste processing and decommissioning, and radiation protection. Serves nuclear power plant operators, research reactors, and new-build programmes.
• NRG PALLAS Academy Training and certification courses in radiation protection and nuclear technology, including Radiation Protection Expert (RPE), Responsible Professional Officer (RPO) for dispersible radioactive substances level D, RPO-NORM courses, and refresher mathematics courses. For nuclear industry professionals requiring certification.
• PALLAS Programme (New-build Reactor) New reactor construction project in Petten, Netherlands, to replace the High Flux Reactor (HFR) and ensure future-proof global supply of medical isotopes. Includes complete nuclear infrastructure supporting both nuclear medicine and scientific research. Open Construction Day held on 2025-06-22.

Quantifiable outcome

• 30,000 patients helped daily with medical isotope products

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• FCC (Grupo FCC)coreImplementation/ SI/ Consulting Partner · 2 June 2026Agreement signed between NRG PALLAS and FCC for supply and installation of hot cells for the new PALLAS-reactor. This is a critical infrastructure partnership for the PALLAS Programme construction.
• Netherlands Cancer Institute (Antoni van Leeuwenhoek Ziekenhuis)coreStrategic or Co-development PartnerMedical isotopes supplied by NRG PALLAS are used at the Netherlands Cancer Institute in Amsterdam for treatment of diseases including prostate cancer with Lutetium-177. Collaborative research relationship in nuclear medicine applications.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Curium Pharma: One of the world's largest nuclear medicine companies, producing Mo-99 and a broad portfolio of SPECT/PET radiopharmaceuticals — directly comparable to NRG PALLAS in isotope production, supply chain, and clinical end markets.
• Institute for Radioelements (IRE): Belgian producer of medical radioisotopes (Mo-99, I-131, Lu-177) and a key European isotope supplier — directly comparable to NRG PALLAS as a European reactor- and cyclotron-based isotope producer serving global radiopharmaceutical demand.
• Lantheus Holdings: Radiopharmaceutical-focused company developing and commercializing diagnostic and therapeutic isotopes including Mo-99/Tc-99m generators and Lu-177-based therapies — directly comparable theranostic and isotope commercialization model.

Regional players

• Australian Nuclear Science and Technology Organisation (ANSTO): Operates OPAL reactor producing Mo-99 and other medical isotopes for global markets, plus nuclear services and research — directly comparable reactor-based isotope model, but serves primarily from Australia/Asia-Pacific rather than Europe.
• Canadian Nuclear Laboratories (CNL) / AECL: Operates research reactors (NRU legacy, new SLOWPOKE-type) and produces medical isotopes including Mo-99 — directly comparable state-backed reactor/isotope operator, but North American rather than European.
• South African Nuclear Energy Corporation (Necsa) / NTP Radioisotopes: Operates the SAFARI-1 reactor producing Mo-99 and a broad radioisotope portfolio for global supply — directly comparable reactor-based isotope producer, but Africa-focused rather than European.

Broad incumbents

• GE HealthCare (PETNET Solutions): Operates a global network of PET tracer manufacturing and distribution facilities (FDG and other radiopharmaceuticals) — overlapping with NRG PALLAS in nuclear medicine supply chain but as part of a much larger medical imaging and diagnostics portfolio.
• Siemens Healthineers: Major diagnostics and imaging incumbent with PET radiopharmacy and broader nuclear medicine footprint — competes in adjacent parts of the nuclear medicine value chain but is not a specialized isotope producer like NRG PALLAS.

Emerging players

• Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company focused on diagnostic and therapeutic isotopes (PSMA imaging, Lu-177 therapy programs) — comparable as a downstream buyer and developer of isotopes that NRG PALLAS produces.
• NorthStar Medical Radioisotopes: US-based company commercializing non-reactor Mo-99 production and expanding into therapeutic isotopes — emerging alternative supplier directly competing with NRG PALLAS in the Mo-99 market and accelerating domestic supply diversification.

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/pallasreactor
• LinkedInlinkedin.com/company/pallas-reactor
• Instagraminstagram.com/nrgpallas

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PALLAS